MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).
Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
https://finance.yahoo.com/news/maxcyte-signs-strategic-platform-license-070000514.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.